{"id":4277,"date":"2014-04-02T12:12:26","date_gmt":"2014-04-02T12:12:26","guid":{"rendered":"\/?p=4277"},"modified":"2014-04-02T12:12:35","modified_gmt":"2014-04-02T12:12:35","slug":"multicell-technologies-inc-otcmktsmcet-enjoys-new-growth","status":"publish","type":"post","link":"\/articles\/multicell-technologies-inc-otcmktsmcet-enjoys-new-growth\/","title":{"rendered":"MultiCell Technologies, Inc. (OTCMKTS:MCET) Enjoys New Growth"},"content":{"rendered":"

MultiCell Technologies, Inc. (OTCMKTS:MCET<\/a>) is in the sweet spot of most pharmaceutical companies- boosted by enough recent developments, and still interesting enough to investors to support a period of significant price growth. On Monday, MCET<\/a> opened the week strongly, with a net daily gain of 40% to $0.0021, on dollar volumes above $1.31 million. MCET<\/a> still remains a double-zero stock, but one that may move under the rules for promising biotech companies. \"MCET0204.png\" <\/p>\n

The latest PR messages from the company outline its efforts to patent its RNA treatments through the US and international protection systems. Still, MCET<\/a> is perceived as a technical trading opportunity, due to the rather low price and the relatively robust volumes. MCET<\/a> is for now not boosted by an email promotion. The rise from triple-zero positions at the beginning of March is also not so unusual on the OTC markets, especially given that MCET<\/a> remains a pure-play pharmaceutical company, with no claims to touching the medical marijuana market. \"ACTC0204.png\"<\/p>\n

To the benefit of MCET<\/a>, the company has a strange stock structure, with 3.15 billion shares outstanding- but a miniature free float of 600,000 shares. Investors’ forums see this as an opportunity to create a short-term squeeze and lift MCET<\/a> to a price of a few cents. Unfortunately, this also means holdings of shares waiting in the sidelines, to be sold off at a moment when the price starts to look right.<\/p>\n

The levels of MCET<\/a> held on as it announced its latest round of financial results at the end of February. The ongoing research and development should rely on the following resources:<\/p>\n